厄贝沙坦联合百令胶囊对早期糖尿病肾病患者尿微量清蛋白/尿肌酐比值及超敏C反应蛋白的影响

Effect of Irbesartan with Bailing Capsules on Microalbuminuria-to-creatinine Ratio and High-sensitive C-reactive Protein in Patients with Early Diabetic Nephropathy

目的观察厄贝沙坦联合百令胶囊对早期糖尿病肾病患者尿微量清蛋白/尿肌酐比值(UmAlb/C)、超敏C反应蛋白(hs-CRP)及血清肌酐(SCr)水平的影响,探讨其对早期糖尿病肾病的保护作用。方法 62例早期2型糖尿病肾病患者被随机分为对照组(厄贝沙坦组)和治疗组(厄贝沙坦联合百令胶囊组),经24周治疗后,观察两组患者的UmAlb/C、hs-CRP、空腹血糖(FBG)、糖化血红蛋白(HbA1c)和SCr水平的变化。结果两组治疗后UmAlb/C、hs-CRP和SCr均降低,与本组治疗前比较,差异有统计学意义(P<0.05),治疗组较对照组降低更显著(P<0.01)。两组治疗后FBG、HbA1c较治疗前略有下降,但差异无统计学意义(P>0.05)。结论厄贝沙坦联合百令胶囊能明显降低早期糖尿病肾病患者UmAlb/C、hs-CRP及SCr的水平,使肾脏损伤程度减低,较单用厄贝沙坦作用明显。

Objective To observe the effect of combined irbesartan and Bailing Capsule （BC） on microalbuminuria-to-creatinine ratio （UmA1b/C）,high C-reactive protein （hs-CRP） and serum creatinin（SCr） in patients with early diabetic nephropathy （DN）.Methods Sixty-two early DN patients were randomized into groups control （using irbesartan）,therapy （using irbesartan with BC）.The changes of UmAlb/C,hs-CRP,fasting blood glucose （FBG）,glycosylated hemoglobin （HbA1c） and SCr were observed after 24 weeks of treatment.Results The post-treatment levels of UmAlb/C,hs-CRP,SCr decreased in 2 groups,significantly different from pre-treatment（P0.05）,lower in therapy group than in control（P0.01）.Post-treatment FBG,HbA1cdecreased slightly as compared with pre-treatment,the difference was not significant（P0. 05）.Conclusion Irbesartan with BC can decrease obviously the levels of UmAlb/C,hs-CRP,SCr,reduce renal damage,having more remarkable effect than single-used irbesartan.